ENDRA Life Sciences Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ENDRA Life Sciences Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 64,899% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 98% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-7.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 53% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-40.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 68% of Healthcare companies in United States.
Cash Cushion Ratio
+4%Cash, after subtracting all debt, equals 4% of its market value (net cash).
Lower than 60% of Healthcare companies in United States.
Tangible Assets Ratio
48%Of every $100 the company owns, $48 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 83% of Healthcare companies in United States.
Tangible Net Worth Ratio
11%Of every $100 of net worth, $11 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 69% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
ENDRA Life Sciences Inc. made a loss over the last year. ENDRA Life Sciences Inc. owes $0.21 for every $1 it owns. ENDRA Life Sciences Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossENDRA Life Sciences Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.14The share price is 1.14 times ENDRA Life Sciences Inc.'s book value per share, lower than 76% of Healthcare companies in United States.
Market cap
$7 MThe total market value of all of ENDRA Life Sciences Inc.'s shares at today's price (share price × number of shares), smaller than 90% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$6 MWhat ENDRA Life Sciences Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.21Net worth divided by the number of shares. The share price of $4.80 is 1.1 times this, which is the P/B above.
Return on equity (ROE)
-152.0%ENDRA Life Sciences Inc. lost 152.0% of its shareholders' money over the last year, lower than 80% of Healthcare companies in United States.
Owes vs Owns
0.21×ENDRA Life Sciences Inc. owes $0.21 for every $1 it owns (low), lower than 71% of Healthcare companies in United States.
Dividend yield
NoneENDRA Life Sciences Inc. does not currently pay a dividend.
Profit growth
LossENDRA Life Sciences Inc. made a loss in each of the last two years.
Cash vs debt
Net cashENDRA Life Sciences Inc. held $0 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For ENDRA Life Sciences Inc.: $7 M ÷ $6 M (30 Jun 2026) = 1.1.
What is ENDRA Life Sciences Inc.'s return on equity?
ENDRA Life Sciences Inc. lost 152.0% of its shareholders' money over the last year, lower than 80% of Healthcare companies in United States.
How much does ENDRA Life Sciences Inc. owe compared with what it owns?
ENDRA Life Sciences Inc. owes $0.21 for every $1 it owns (low), lower than 71% of Healthcare companies in United States.
Does ENDRA Life Sciences Inc. pay a dividend?
No. ENDRA Life Sciences Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.